Skip to main content
SpringerLink
Log in

Modulatory effect of berberine on plasma lipoprotein (or lipid) profile: a review

  • Review
  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Berberine is a bioactive isoquinoline alkaloid compound extracted from various medicinal plants, such as Barberry. Berberine shows various pharmacological properties that are mainly attributed to its anti-inflammatory and antioxidant effects. A growing body of evidence has shown that berberine influences cholesterol metabolism, and consequently, may ameliorate dyslipidemias and atherosclerosis. Plasma high-density lipoprotein cholesterol (HDL-C) is known to have an independent negative association with incident cardiovascular disease (CVD). However, several outcomes trials and genetic studies have failed to meet expecting the beneficial effects of elevating plasma HDL-C concentrations. Hence, investigations are currently focused on enhancing the functionality of HDL particles, independent of their plasma concentrations. HDL particles show various qualities because of a heterogeneous composition. Consistent with complex metabolism and composition, various biological functions are found for HDL, such as anti-inflammatory, antioxidant, anti-apoptotic, and anti-thrombotic activities. Protective effects of berberine may impact the functionality of HDL; therefore, the present literature review was intended to determine whether berberine can amplify HDL function. It was concluded that berberine may regulate markers of HDL activity, such as apo-AI, cholesterol efflux, LCAT, PON1, and S1P activities and levels. Consequently, berberine may recuperate conditions with dysfunctional HDL and, therefore, have the potential to emerge as a therapeutic agent. However, further human trials of berberine are warranted to evaluate its impact on HDL function and cholesterol metabolism.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Zhou L, Li C, Gao L, Wang A (2015) High-density lipoprotein synthesis and metabolism. Mol Med Rep 12(3):4015–4021

    Article  CAS  PubMed  Google Scholar 

  2. Ouimet M, Barrett TJ, Fisher EA (2019) HDL and reverse cholesterol transport: Basic mechanisms and their roles in vascular health and disease. Circul Res 124(10):1505–1518

    Article  CAS  Google Scholar 

  3. Camont L, Chapman MJ, Kontush A (2011) Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med 17(10):594–603

    Article  CAS  PubMed  Google Scholar 

  4. Rader DJ (2006) Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Investig 116(12):3090–3100

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Mulya A, Lee J-Y, Gebre AK, Thomas MJ, Colvin PL, Parks JS (2007) Minimal lipidation of pre-β HDL by ABCA1 results in reduced ability to interact with ABCA1. Arteriosclerosis, thrombosis, and vascular biology. 27:1828–18368

  6. Adorni MP, Zimetti F, Billheimer JT, Wang N, Rader DJ, Phillips MC et al (2007) The roles of different pathways in the release of cholesterol from macrophages. J Lipid Res 48(11):2453–2462

    Article  CAS  PubMed  Google Scholar 

  7. Wang M, Briggs MR (2004) HDL: the metabolism, function, and therapeutic importance. Chem Rev 104(1):119–138

    Article  CAS  PubMed  Google Scholar 

  8. Oosterveer DM, Versmissen J, Yazdanpanah M, Defesche JC, Kastelein JJ, Sijbrands EJ (2009) The risk of tendon xanthomas in familial hypercholesterolaemia is influenced by variation in genes of the reverse cholesterol transport pathway and the low-density lipoprotein oxidation pathway. Eur Heart J 31(8):1007–1012

    Article  PubMed  Google Scholar 

  9. Collet X, Tall AR, Serajuddin H, Guendouzi K, Royer L, Oliveira H et al (1999) Remodeling of HDL by CETP in vivo and by CETP and hepatic lipase in vitro results in enhanced uptake of HDL CE by cells expressing scavenger receptor BI. J Lipid Res 40(7):1185–1193

    Article  CAS  PubMed  Google Scholar 

  10. Rysz-Górzyńska M, Banach M (2016) Subfractions of high-density lipoprotein (HDL) and dysfunctional HDL in chronic kidney disease patients. Archives of medical science: AMS 12(4):844

    Article  PubMed  PubMed Central  Google Scholar 

  11. Pirro M, Vaudo G, Lupattelli G, Pasqualini L, Mannarino MR, Schillaci G et al (2013) On-treatment C-reactive protein and HDL cholesterol levels in patients at intermediate cardiovascular risk: impact on carotid intima-media thickness. Life Sci 93(8):338–343

    Article  CAS  PubMed  Google Scholar 

  12. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD et al (1989) High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79(1):8–15

    Article  CAS  PubMed  Google Scholar 

  13. Boekholdt SM, Arsenault BJ, Hovingh GK, Mora S, Pedersen TR, LaRosa JC et al (2013) Levels and changes of HDL cholesterol and apolipoprotein AI in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. Circulation 128(14):1504–1512

    Article  CAS  PubMed  Google Scholar 

  14. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK et al (2012) Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. The Lancet 380(9841):572–580

    Article  CAS  Google Scholar 

  15. Investigators A-H (2011) Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365(24):2255–2267

    Article  Google Scholar 

  16. Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, Davidson M, Rysz J, Banach M (2012) Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 51(4):314–324

    Article  CAS  PubMed  Google Scholar 

  17. Barylski M, Toth PP, Nikolic D, Banach M, Rizzo M, Montalto G (2014) Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality. Best Pract Res Clin Endocrinol Metab 28(3):453–461

    Article  CAS  PubMed  Google Scholar 

  18. de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH (2010) The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol 30(4):796–801

    Article  PubMed  PubMed Central  Google Scholar 

  19. Van Eck M, Twisk J, Hoekstra M, Van Rij BT, Van der Lans CA, Bos IST et al (2003) Differential effects of scavenger receptor BI deficiency on lipid metabolism in cells of the arterial wall and the liver. Journal of Biological Chemistry.

  20. Van Eck M, Hoekstra M, Hildebrand RB, Yaong Y, Stengel D, Kruijt JK et al (2007) Increased oxidative stress in scavenger receptor BI knockout mice with dysfunctional HDL. Arteriosclerosis, thrombosis, and vascular biology. 27:2413–241911

  21. Ganjali S, Momtazi AA, Banach M, Kovanen PT, Stein EA, Sahebkar A (2017) HDL abnormalities in familial hypercholesterolemia: Focus on biological functions. Prog Lipid Res 67:16–26

    Article  CAS  PubMed  Google Scholar 

  22. Soran H, Hama S, Yadav R, Durrington PN (2012) HDL functionality. Curr Opin Lipidol 23(4):353–366

    Article  CAS  PubMed  Google Scholar 

  23. Fielding CJ, Fielding PE (1995) Molecular physiology of reverse cholesterol transport. J Lipid Res 36(2):211–228

    Article  CAS  PubMed  Google Scholar 

  24. Navab M, Reddy ST, Van Lenten BJ, Anantharamaiah G, Fogelman AM (2009) The role of dysfunctional HDL in atherosclerosis. J Lipid Res 50(Supplement):S145–S9

    Article  PubMed  PubMed Central  Google Scholar 

  25. Van Lenten BJ, Wagner AC, Navab M, Anantharamaiah G, Hama S, Reddy ST et al (2007) Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits. J Lipid Res 48(11):2344–2353

    Article  PubMed  Google Scholar 

  26. Smith JD (2008) Inflammation impairs reverse cholesterol transport in vivo. Am Heart Assoc

  27. Vaisar T, Tang C, Babenko I, Hutchins P, Wimberger J, Suffredini AF et al (2015) Inflammatory remodeling of the HDL proteome impairs cholesterol efflux capacity. Journal of lipid research. :jlr. M059089

  28. Ferretti G, Bacchetti T, Masciangelo S, Bicchiega V (2010) HDL-paraoxonase and Membrane Lipid Peroxidation: A Comparison Between Healthy and Obese Subjects. Obesity 18(6):1079–1084

    Article  CAS  PubMed  Google Scholar 

  29. Sentí M, Tomás M, Fitó M, Weinbrenner T, Covas Ma I, Sala J et al (2003) Antioxidant paraoxonase 1 activity in the metabolic syndrome. J Clin Endocrinol Metabolism 88(11):5422–5426

    Article  Google Scholar 

  30. Mackness M, Mackness B (2015) Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles. Gene 567(1):12–21

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Pasqualini L, Cortese C, Marchesi S, Siepi D, Pirro M, Vaudo G et al (2005) Paraoxonase-1 activity modulates endothelial function in patients with peripheral arterial disease. Atherosclerosis 183(2):349–354

    Article  CAS  PubMed  Google Scholar 

  32. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K et al (2011) Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364(2):127–135

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Van Wijk J, Coll B, Cabezas MC, Koning E, Camps J, Rabelink T et al (2006) Rosiglitazone modulates fasting and post-prandial paraoxonase 1 activity in type 2 diabetic patients. Clin Exp Pharmacol Physiol 33(12):1134–1137

    Article  PubMed  Google Scholar 

  34. Tang J, Feng Y, Tsao S, Wang N, Curtain R, Wang Y (2009) Berberine and Coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations. J Ethnopharmacol 126(1):5–17

    Article  CAS  PubMed  Google Scholar 

  35. Zhang Q, Piao X-L, Piao X-S, Lu T, Wang D, Kim SW (2011) Preventive effect of Coptis chinensis and berberine on intestinal injury in rats challenged with lipopolysaccharides. Food Chem Toxicol 49(1):61–69

    Article  CAS  PubMed  Google Scholar 

  36. Kumar A, Chopra K, Mukherjee M, Pottabathini R, Dhull DK (2015) Current knowledge and pharmacological profile of berberine: an update. Eur J Pharmacol 761:288–297

    Article  CAS  PubMed  Google Scholar 

  37. Cicero AF, Baggioni A (2016) Berberine and its role in chronic disease. Springer, Anti-inflammatory Nutraceuticals and Chronic Diseases, pp 27–45

    Google Scholar 

  38. Ayati SH, Fazeli B, Momtazi-Borojeni AA, Cicero AF, Pirro M, Sahebkar A (2017) Regulatory effects of berberine on microRNome in cancer and other conditions. Crit Rev Oncol/Hematol 116:147–158

    Article  Google Scholar 

  39. Li X-Y, Zhao Z-X, Huang M, Feng R, He C-Y, Ma C et al (2015) Effect of Berberine on promoting the excretion of cholesterol in high-fat diet-induced hyperlipidemic hamsters. J Translational Med 13(1):1–9

    Article  Google Scholar 

  40. Stein TD, Anders NJ, DeCarli C, Chan SL, Mattson MP, Johnson JA (2004) Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPSW mice resulting in tau phosphorylation and loss of hippocampal neurons: support for the amyloid hypothesis. The Journal of neuroscience: the official journal of the Society for Neuroscience. 24(35):7707-17.

  41. Zhang M, Feng L, Li J, Chen L (2016) Therapeutic Potential and Mechanisms of Berberine in Cardiovascular Disease. Curr Pharmacol Rep 2(6):281–292

    Article  CAS  Google Scholar 

  42. Ju, J., Li, J., Lin, Q., & Xu, H. (2018). Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials. Phytomedicine : international journal of phytotherapy and phytopharmacology, 50, 25–34.

  43. Wang, Y., & Zidichouski, J. A. (2018). Update on the Benefits and Mechanisms of Action of the Bioactive Vegetal Alkaloid Berberine on Lipid Metabolism and Homeostasis. Cholesterol, 2018, 7173920.

  44. Goldstein JL, Brown MS (2009) The LDL receptor. Arteriosclerosis, thrombosis, and vascular biology. 29(4):431–438

  45. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C et al (2004) Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 10(12):1344

    Article  CAS  PubMed  Google Scholar 

  46. Wang Y, Yi X, Ghanam K, Zhang S, Zhao T, Zhu X (2014) Berberine decreases cholesterol levels in rats through multiple mechanisms, including inhibition of cholesterol absorption. Metabolism 63(9):1167–1177

    Article  CAS  PubMed  Google Scholar 

  47. Gu S, Cao B, Sun R, Tang Y, Paletta JL, Wu X-L et al (2015) A metabolomic and pharmacokinetic study on the mechanism underlying the lipid-lowering effect of orally administered berberine. Mol Biosyst 11(2):463–474

    Article  CAS  PubMed  Google Scholar 

  48. Li Y-H, Yang P, Kong W-J, Wang Y-X, Hu C-Q, Zuo Z-Y et al (2008) Berberine Analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure – activity relationships, and cholesterol-lowering efficacy. J Med Chem 52(2):492–501

    Article  Google Scholar 

  49. He K, Ye X, Wu H, Wang Y, Zou Z, Ning N et al (2015) The safety and anti-hypercholesterolemic effect of coptisine in Syrian golden hamsters. Lipids 50(2):185–194

    Article  CAS  PubMed  Google Scholar 

  50. Abidi P, Zhou Y, Jiang J-D, Liu J (2005) Extracellular signal-regulated kinase–dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine. Arteriosclerosis, thrombosis, and vascular biology. 25:2170–217610

  51. Momtazi AA, Banach M, Pirro M, Katsiki N, Sahebkar A (2017) Regulation of PCSK9 by nutraceuticals. Pharmacol Res 120:157–169

    Article  CAS  PubMed  Google Scholar 

  52. Wang Y, Han Y, Chai F, Xiang H, Huang T, Kou S et al (2016) The antihypercholesterolemic effect of columbamine from Rhizoma Coptidis in HFHC-diet induced hamsters through HNF-4α/FTF-mediated CYP7A1 activation. Fitoterapia 115:111–121

    Article  CAS  PubMed  Google Scholar 

  53. Wang Y, Jia X, Ghanam K, Beaurepaire C, Zidichouski J, Miller L (2010) Berberine and plant stanols synergistically inhibit cholesterol absorption in hamsters. Atherosclerosis 209(1):111–117

    Article  CAS  PubMed  Google Scholar 

  54. Li X-Y, Zhao Z-X, Huang M, Feng R, He C-Y, Ma C et al (2015) Effect of Berberine on promoting the excretion of cholesterol in high-fat diet-induced hyperlipidemic hamsters. J translational Med 13(1):278

    Article  Google Scholar 

  55. Kuo C-L, Chi C-W, Liu T-Y (2004) The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett 203(2):127–137

    Article  CAS  PubMed  Google Scholar 

  56. Xiao H-B, Sun Z-L, Zhang H-B, Zhang D-S (2012) Berberine inhibits dyslipidemia in C57BL/6 mice with lipopolysaccharide induced inflammation. Pharmacol Rep 64(4):889–895

    Article  CAS  PubMed  Google Scholar 

  57. Wang FL, Tang LQ, Yang F, Zhu LN, Cai M, Wei W (2013) Renoprotective effects of berberine and its possible molecular mechanisms in combination of high-fat diet and low-dose streptozotocin-induced diabetic rats. Mol Biol Rep 40(3):2405–2418

    Article  CAS  PubMed  Google Scholar 

  58. Zhang W, Xu Y-c, Guo F-j, Meng Y, Li M-l (2008) Anti-diabetic effects of cinnamaldehyde and berberine and their impacts on retinol-binding protein 4 expression in rats with type 2 diabetes mellitus. Chin Med J (English Edition) 121(21):2124

    CAS  Google Scholar 

  59. Leng S-H, Lu F-E, Xu L-J (2004) Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacol Sin 25(4):496–502

    CAS  PubMed  Google Scholar 

  60. He K, Kou S, Zou Z, Hu Y, Feng M, Han B et al (2016) Hypolipidemic effects of alkaloids from Rhizoma coptidis in diet-induced hyperlipidemic hamsters. Planta Med 82(08):690–697

    Article  CAS  PubMed  Google Scholar 

  61. Hu Y, Davies GE (2010) Berberine inhibits adipogenesis in high-fat diet-induced obesity mice. Fitoterapia 81(5):358–366

    Article  CAS  PubMed  Google Scholar 

  62. Chang X-x, Xu YH, Xia Q, Bian M-f, Zhu H (2012) The effects of berberine on hyperhomocysteinemia and hyperlipidemia in rats fed with a long-term high-fat diet. Lipids Health Dis 11(1):86

    Article  PubMed  PubMed Central  Google Scholar 

  63. Hu Y, Ehli EA, Kittelsrud J, Ronan PJ, Munger K, Downey T et al (2012) Lipid-lowering effect of berberine in human subjects and rats. Phytomedicine 19(10):861–867

    Article  CAS  PubMed  Google Scholar 

  64. Li G-S, Liu X-H, Zhu H, Huang L, Liu Y-L, Ma C-M et al (2011) Berberine-improved visceral white adipose tissue insulin resistance associated with altered sterol regulatory element-binding proteins, liver X receptors, and peroxisome proliferator-activated receptors transcriptional programs in diabetic hamsters. Biol Pharm Bull 34(5):644–654

    Article  CAS  PubMed  Google Scholar 

  65. D'Addato, S., Scandiani, L., Mombelli, G., Focanti, F., Pelacchi, F., Salvatori, E., Di Loreto, G., Comandini, A., Maffioli, P., & Derosa, G. (2017). Effect of a food supplement containing berberine, monacolin K, hydroxytyrosol and coenzyme Q10 on lipid levels: a randomized, double-blind, placebo controlled study. Drug design, development and therapy, 11, 1585–1592.

  66. Millán J, Cicero AF, Torres F, Anguera A (2016) Effects of a nutraceutical combination containing berberine (BRB), policosanol, and red yeast rice (RYR), on lipid profile in hypercholesterolemic patients: a meta-analysis of randomised controlled trials. Clin e investigacion en Arterioscler 28(4):178–187

    Article  Google Scholar 

  67. Wei, X., Wang, C., Hao, S., Song, H., & Yang, L. (2016). The Therapeutic Effect of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis. Evidence-based complementary and alternative medicine : eCAM, 2016, 3593951.

  68. Lan J, Zhao Y, Dong F, Yan Z, Zheng W, Fan J et al (2015) Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol 161:69–81

    Article  CAS  PubMed  Google Scholar 

  69. Weng TC, Yang YHK, Lin SJ, Tai SH (2010) A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther 35(2):139–151

    Article  CAS  PubMed  Google Scholar 

  70. Cicero AF, Colletti A, Bajraktari G, Descamps O, Djuric DM, Ezhov M et al (2017) Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Nutr Rev 75(9):731–767

    Article  PubMed  Google Scholar 

  71. Heinecke JW (2009) The HDL proteome: a marker–and perhaps mediator–of coronary artery disease. J Lipid Res 50(Supplement):S167–S71

    Article  PubMed  PubMed Central  Google Scholar 

  72. Hassan MKN, Ali RM, Amom ZH, Arshad MSM, Shah ZM, Kadir KKA et al (2014) Effect of apigenin, berberine and rutin on cholesterol metabolism in Hep G2 cancer cell. SAINS MALAYSIANA 43(4):559–566

    Google Scholar 

  73. Liu D-l, Xu L-j, Dong H, Chen G, Huang Z-y, Zou X et al (2015) Inhibition of proprotein convertase subtilisin/kexin type 9: a novel mechanism of berberine and 8-hydroxy dihydroberberine against hyperlipidemia. Chin J Integr Med 21(2):132–138

    Article  CAS  PubMed  Google Scholar 

  74. Zhou JY, Zhou SW, Zhang KB, Tang JL, Guang LX, Ying Y et al (2008) Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats. Biol Pharm Bull 31(6):1169–1176

    Article  CAS  PubMed  Google Scholar 

  75. Solà R, Valls R-M, Puzo J, Calabuig J-R, Brea A, Pedret A et al (2014) Effects of poly-bioactive compounds on lipid profile and body weight in a moderately hypercholesterolemic population with low cardiovascular disease risk: a multicenter randomized trial. PLoS ONE 9(8):e101978

    Article  PubMed  PubMed Central  Google Scholar 

  76. Brinton EA, Eisenberg S, Breslow JL (1994) Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arterioscler Thromb Vasc Biol 14(5):707–720

    Article  CAS  Google Scholar 

  77. Zhan X, Chen Y, Yan C, Liu S, Deng L, Yang Y et al (2018) Apolipoprotein B/apolipoprotein A1 ratio and mortality among incident peritoneal dialysis patients. Lipids Health Dis 17(1):117

    Article  PubMed  PubMed Central  Google Scholar 

  78. Lee TS, Pan CC, Peng CC, Kou YR, Chen CY, Ching LC et al (2010) Anti-atherogenic effect of berberine on LXRα‐ABCA1‐dependent cholesterol efflux in macrophages. J Cell Biochem 111(1):104–110

    Article  CAS  PubMed  Google Scholar 

  79. LIU X-y YAN, S-m GONGH (2009) ZHAO X-l, CHEN F-l. Effects of berberine on cholesterol efflux in THP-1 macrophage derived foam cells. J Shanghai Jiaotong Univ (Medical Science) 1415-18

    Google Scholar 

  80. Huang Z, Dong F, Li S, Chu M, Zhou H, Lu Z et al (2012) Berberine-induced inhibition of adipocyte enhancer-binding protein 1 attenuates oxidized low-density lipoprotein accumulation and foam cell formation in phorbol 12-myristate 13-acetate-induced macrophages. Eur J Pharmacol 690(1–3):164–169

    Article  CAS  PubMed  Google Scholar 

  81. Majdalawieh A, Zhang L, Fuki IV, Rader DJ, Ro H-S (2006) Adipocyte enhancer-binding protein 1 is a potential novel atherogenic factor involved in macrophage cholesterol homeostasis and inflammation. Proceedings of the National Academy of Sciences. 103(7):2346-51

  82. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM (1998) PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93(2):241–252

    Article  CAS  PubMed  Google Scholar 

  83. Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, Edwards PA et al (2000) Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXRα. Proceedings of the National Academy of Sciences. 97(22):12097-102

  84. Chawla A, Boisvert WA, Lee C-H, Laffitte BA, Barak Y, Joseph SB et al (2001) A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7(1):161–171

    Article  CAS  PubMed  Google Scholar 

  85. Laffitte BA, Repa JJ, Joseph SB, Wilpitz DC, Kast HR, Mangelsdorf DJ et al (2001) LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proceedings of the National Academy of Sciences. 98(2):507 – 12

  86. Akiyama TE, Sakai S, Lambert G, Nicol CJ, Matsusue K, Pimprale S et al (2002) Conditional disruption of the peroxisome proliferator-activated receptor γ gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol 22(8):2607–2619

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Liang H, Wang Y (2018) Berberine alleviates hepatic lipid accumulation by increasing ABCA1 through the protein kinase C δ pathway. Biochem Biophys Res Commun 498(3):473–480

    Article  CAS  PubMed  Google Scholar 

  88. Linton MF, Tao H, Linton EF, Yancey PG (2017) SR-BI: a multifunctional receptor in cholesterol homeostasis and atherosclerosis. Trends in Endocrinology & Metabolism 28(6):461–472

    Article  CAS  Google Scholar 

  89. Guan S, Wang B, Li W, Guan J, Fang X (2010) Effects of berberine on expression of LOX-1 and SR-BI in human macrophage-derived foam cells induced by ox-LDL. Am J Chin Med 38(06):1161–1169

    Article  CAS  PubMed  Google Scholar 

  90. Yang X-J, Liu F, Feng N, Ding X-S, Chen Y, Zhu S-X et al (2020) Berberine attenuates cholesterol accumulation in macrophage foam cells by suppressing AP-1 activity and activation of the Nrf2/HO-1 pathway. J Cardiovasc Pharmacol 75(1):45–53

    Article  CAS  PubMed  Google Scholar 

  91. Jin L, He Q, Zhou Q, YANG J-x (2010) Effect of berberine on lipid metabolism and expressions of low density lipoprotein receptor and scavenger receptor class-B type 1 genes in livers of hyperlipidemic rabbits. Chin J Biol 23:1226–1229

    CAS  Google Scholar 

  92. Rousset X, Vaisman B, Amar M, Sethi AA, Remaley AT (2009) Lecithin: cholesterol acyltransferase: from biochemistry to role in cardiovascular disease. Curr Opin Endocrinol Diabetes Obes 16(2):163

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Cheng C-C, Hsueh C-M, Liang K-W, Ting C-T, Wen C-L, Hsu S-L (2011) Role of JNK and c-Jun signaling pathway in regulation of human serum paraoxonase 1 gene transcription by berberine in human HepG2 cells. Eur J Pharmacol 650(2–3):519–525

    Article  CAS  PubMed  Google Scholar 

  94. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN (1995) Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arteriosclerosis, thrombosis, and vascular biology. 15:1812–181811

  95. Tavernier G, Caspar-Bauguil S, Viguerie N, Apolipoprotein M (2020) New connections with diet, adipose tissue and metabolic syndrome. Curr Opin Lipidol 31(1):8–14

    Article  CAS  PubMed  Google Scholar 

  96. Levkau B (2015) HDL-S1P: cardiovascular functions, disease-associated alterations, and therapeutic applications. Front Pharmacol 6:243

    Article  PubMed  PubMed Central  Google Scholar 

  97. Liu XH, Li GS, Huang L, Zhu H, Liu YL, Ma CM (2011) Effects of berberine on expression of hepatic sterol regulatory element-binding protein, its control and target genes in type 2 diabetic Chinese hamsters. J Dalian Med Univ 33(1):23–30 Chinese

    CAS  Google Scholar 

  98. Lan T, Shen X, Liu P, Liu W, Xu S, Xie X et al (2010) Berberine ameliorates renal injury in diabetic C57BL/6 mice: Involvement of suppression of SphK–S1P signaling pathway. Arch Biochem Biophys 502(2):112–120

    Article  CAS  PubMed  Google Scholar 

  99. PENG J, LAN T, HUANG K-p HUANGJ, XIE X (2011) HUANG H-q. Berberine ameliorates diabetic mouse renal injury through inhibition of SphK1-S1P signaling pathway [J]. Chin Pharmacol Bull 11:020

    Google Scholar 

  100. Huang K, Liu W, Lan T, Xie X, Peng J, Huang J et al (2012) Berberine reduces fibronectin expression by suppressing the S1P-S1P2 receptor pathway in experimental diabetic nephropathy models. PLoS ONE 7(8):e43874

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Mortazavi, H., Nikfar, B., Esmaeili, S. A., Rafieenia, F., Saburi, E., Chaichian, S., Heidari Gorji, M. A., & Momtazi-Borojeni, A. A. (2020). Potential cytotoxic and anti-metastatic effects of berberine on gynaecological cancers with drug-associated resistance. European journal of medicinal chemistry, 187, 111951. https://doi.org/10.1016/j.ejmech.2019.111951

Download references

Acknowledgements

None declared.

Author information

Authors and Affiliations

  1. Otorhinolaryngology-Head & Neck Surgery, Faculty of Medicine, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

    Navid Nourizadeh

  2. Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

    Leila Vazifeh Mostaan

  3. Department of Medical Genetics and Molecular Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

    Ehsan Saburi

  4. Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

    Seyed Isaac Hashemy

  5. Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

    Seyed Isaac Hashemy

Authors
  1. Navid Nourizadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leila Vazifeh Mostaan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ehsan Saburi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seyed Isaac Hashemy
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Study conception or design: SEH, ES, LVM, and NN; Data collection and draft manuscript preparation: SEH, ES; Critical revision of the paper: SEH, ES, LVM, and NN; Final approval of the version to be published SEH, ES, LVM, and NN.

Corresponding authors

Correspondence to Ehsan Saburi or Seyed Isaac Hashemy.

Ethics declarations

Compliance with ethical standards

The authors declare any conflict of interest. Research is not involving Human Participants and/or Animals.

Informed consent

or another Ethical Statement were not applicable.

Source of founding

None declared.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nourizadeh, N., Vazifeh Mostaan, L., Saburi, E. et al. Modulatory effect of berberine on plasma lipoprotein (or lipid) profile: a review. Mol Biol Rep 49, 10885–10893 (2022). https://doi.org/10.1007/s11033-022-07623-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-022-07623-7

Keywords

Search

Navigation